HER2 Positive Untreated Metastatic Breast Cancer Terminated Phase 1 Trials for Pertuzumab (DB06366)

IndicationStatusPhase
DBCOND0077040 (HER2 Positive Untreated Metastatic Breast Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02598427Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast CancerTreatment